Skip to content

Assessment of Interstitial Lung Disease in Rheumatoid Arthritis by Lung Ultrasound

Assessment of Interstitial Lung Disease in Rheumatoid Arthritis by Lung Ultrasound

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04195789
Acronym
PO-PID
Enrollment
34
Registered
2019-12-12
Start date
2020-08-04
Completion date
2024-06-04
Last updated
2024-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Diseases, Lung Diseases, Interstitial, Rheumatoid Arthritis

Brief summary

The high resolution chest scan is the gold standard for the screening of interstitial lung disease, but this remains an onerous examination, and irradiating. Ultrasound could be used to detect these disorders with a very good sensitivity and specificity. This exam offers the advantage of being non radiating, inexpensive, and accessible to the rheumatologist who already uses it in their daily practice. The investigators want to assess the lung ultrasound performance compared with the gold standard. Patients will be included during a regular follow-up consultation with their referent rheumatologist. If there is an indication of first line biotherapy or targeted therapy the doctor will propose to the patient to participate in the study, give him the information leaflet, collect orally non-opposition, and will complete a survey for evaluation of the general health and potential risk factors for interstitial lung.

Interventions

OTHERLung sonography

Realization of a lung sonography with scoring of the number of B-lines exploring 14 intercostal spaces. Duration of the exam : twenty minutes. Recording for a second analysis by another lung specialist.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men and women over the age of 18 * With rheumatoid arthritis meeting the criteria ACR (American College of Rheumatology)/ EULAR (EUropean League Against Rheumatism) 2010 * Never received any biotherapy or targeted therapy * Having an indication of introduction of biotherapy or therapy targeted (JAK inhibitors) (JAK : Janus kinase)

Exclusion criteria

* Refusal to participate in the study * Known pulmonary disease that can alter lung interstitium: cardiac decompensation, COPD (chronic obstructive pulmonary disease), thoracic surgery, infection pulmonary * Patient with respiratory functional signs suggestive of PID (Diffuse interstitial lung disease) * Patient with signs of cardiac decompensation * Patient with pulmonary auscultation suggestive of PID * Pregnant or lactating woman * Psychiatric pathology seriously hindering understanding * Difficulty understanding oral French * Person deprived of liberty or under legal protection

Design outcomes

Primary

MeasureTime frameDescription
Sensibility and specificity of the lung sonography for interstitial lung disease screening in rheumatoid arthritis patients.Month 12To estimate the sensitivity and specificity of pulmonary ultrasound compared to CT scans in patients with rheumatoid arthritis consulting at the Lyon South Hospital Centre or the Edouard Herriot Hospital for the start-up of biotherapy or targeted therapy. (CT : computerized tomography)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026